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Accumulating lines of evidence have revealed that microRNAs (miRNAs) play critical roles in many biological 
processes, such as carcinogenesis, angiogenesis, programmed cell death, cell proliferation, invasion, migration, 
and differentiation. They act either as tumor suppressors or oncogenes, and alteration in their expression 
patterns has been linked to onset, progression and chemoresistance of various cancers. Moreover, miRNAs are 
also crucial for the regulation of cancer stem cells (CSCs) self-renewal and proliferation as well as control of 
Epithelial-to-Mesenchymal Transition (EMT) of cancer cells. Therefore, exploitation of miRNAs as targets for 
cancer prevention and therapy could be a promising approach. Several experimental and epidemiologic studies 
have shown that dietary intake of natural agents such as baicalin, ginsenoside, curcumin, resveratrol, genistein, 
epigallocatechin-3-gallate (EGCG), indole-3-carbinol, 3,3΄-diindolylmethane (DIM) including antioxidants 
among others is inversely associated with the risk for cancer, demonstrating the inhibitory effects of natural 
agents on carcinogenesis. Additionally, the anticancer agents from natural agents have been found to inhibit the 
development and progression of cancer through the regulation of various cancer processes such as apoptosis, cell 
cycle regulation, differentiation, inflammation, angiogenesis, and metastasis. Importantly, natural agents could 
significantly impact the expression of tumor-suppressor and oncogenic miRNAs, regulate cellular signaling 
networks, inhibit cancer cell growth and cancer stem cell self-renewal. This is important for the normalization of 
altered cellular signaling mechanisms in cancer cells. This postulates a much broader use of natural agents in the 
prevention and/or treatment of various cancers in combination with conventional chemotherapeutics. However, 
more in vitro mechanistic experiments, in vivo animal studies, and clinical trials are warranted to realize the true 
value of natural agents in the prevention and/or treatment of cancer. Herein, we provide an overview of natural 
agents’ modulation of miRNA expression as well as highlight the significance of these observations as potential 
new strategies in cancer therapies. This review will help us to understand how miRNAs are regulated by natural 
agents and also help in the development of effective and secure natural agents for therapeutic purposes. 
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Introduction 
Cancer is a complex, multi-step disease characterized by 
disruption of the homeostatic balance between cell 
proliferation and cell death, and uncontrolled, uncoordinated 
and purposeless clonal expansion leading to tumor formation. 
Worldwide, it was estimated that 14.1 million new cancer 
cases and 8.2 million cancer deaths occurred in 2012, with 
32.6 million people reported to be living with cancer having 
been diagnosed in the past five years [1]. It is projected that 
the number of new cancer cases may increase to 19.3 million 
by 2025 due to global population aging. Surgery, radiation, 
and chemotherapy are among the modalities used in cancer 
treatment, whose goal is to either cure the disease or prolong 
and improve the patient’s quality of life. Although 
chemotherapy has led to improvement in this aspect, drug 
resistance and toxicities remains a significant challenge [2]. 
Thus, there is an urgent need to identify safer but equally 
effective agents to be used in cancer treatments, which can be 
found in natural agents. 
For many decades, protein-coding genes were the primary 
focus of cancer research, however, over the past two decades 
there has been a major paradigm shift with the emerging role 
of miRNAs and other epigenetic mechanisms as major 
players [3-5]. Numerous studies have shown that miRNAs not 
only are involved in the process of cell development and 
differentiation, but also play a critical role in carcinogenesis 
[6]. To date, more than 2,400 miRNAs have been identified in 
humans [7], and it is estimated that more than 30% of human 
genes may be regulated by miRNAs [8]. Moreover, 
approximately 50% of the known miRNAs are reported to be 
located in cancer–associated genomic regions [9] and miRNA 
dysregulation has been detected in various cancer cells [10]. 
Therefore, aberrations in miRNA expression patterns are 
thought to be involved in the progression of human cancers 
[11].  
Emerging data suggest that several classes of naturally 
occurring, plant-derived compounds (natural agents) could 
potentially regulate the expression of several miRNAs 
involved in cancer. ‘Natural agents’ as referred to here are 
plant chemicals that have various applications including 
anti-inflammatory, anti-oxidative, anti-proliferation, 
anti-bacterial, anti-viral, and anticancer [12]. These agents are 
widely distributed in various fruits, vegetables, herbs, 
beverages, and many other dietary supplements. Numerous 
studies have demonstrated that the intake of fruit- and 
vegetable-rich foods decreases the occurrence of cancer 
[13-15]. So far, more than 10,000 natural agents have been 
identified [16], and a significant number show anticancer 
potential with no or minimal toxicity to normal cells [17]. Not 
surprisingly therefore, more than 45% of FDA approved 
anticancer drugs are derived from plants [18]. Moreover, these 
natural agents could be used as a single chemotherapeutic 
agent or in association with standard anticancer drugs. They 
can increase the efficacy of anticancer drugs synergistically, 
while reducing the toxic side effects of the standard 
chemotherapeutic drugs [19, 20]. Generally, they exert their 
anticancer and other effects through modulation of multiple 
molecular targets affecting various signaling pathways [16, 21]. 
This is beneficial as malignant transformation and 
progression are multistage processes caused by gene 
alterations in more than one signaling pathway. This is one 
of the most plausible explanations why monomodal therapy 
typically fails in cancer treatments as the specific inhibitors 
often target only a single gene in a signaling pathway [22]. 
Although natural agents including Traditional Chinese 
Medicine (TCM) are known to regulate multiple signaling 
pathways involved in carcinogenesis, the mechanism by 
which they simultaneously interferes with these pathways 
remains unclear. One probable explanation is that some 
botanicals have the capacity to regulate miRNAs associated 
with cancer [23]. Herein, we provide a brief overview of 
natural agents’ modulation of miRNA expression and their 
potential role in cancer treatment and prevention. 
Brief overview of MicroRNAs (miRNAs) 
MicroRNAs (miRNAs) are endogenous, short (18–26 
nucleotides long), evolutionarily conserved, non-coding 
RNAs that regulate gene expression at the 
post-transcriptional level and play an important role in the 
regulation of several cellular, physiological, and 
developmental processes [24]. It is now known that thousands 
of functional miRNAs exist which are widely expressed in 
plants and animals and regulate the expression of more than 
30% of proteins which are closely related to biological 
processes, such as cell growth, proliferation, differentiation, 
migration and apoptosis [25-27].  
The biogenesis of miRNAs is well documented (Figure 1) 
and the involvement of miRNAs in regulation of 
cancer-related events is well established [28]. These small 
non-coding RNAs are believed to be involved in every single 
aspect of the development and progression of human cancers. 
Pertinently, miRNAs are de-regulated in cancer cells with 
reduced expression of tumor suppressor miRNAs and 
increased expression of oncogenic miRNAs, relative to 
normal tissue (Table 1). Consequently, miRNAs have been 
shown to affect cardinal features of cancer such as sustaining 
proliferative signaling, evading growth suppressors, resisting 
cell death, enabling replicative immortality, inducing 
angiogenesis, and activating invasion and metastasis [29-32] 
(Figure 2). Thus, alteration of miRNA expression and 
function may contribute to the initiation, maintenance, and 
progression of tumors as well as to invasiveness, metastasis, 
and acquisition of drug resistance in cancer [33, 34]. 
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Since their discovery, miRNAs have provided us with 
novel insights and ground-breaking impulses to enhance our 
understanding of molecular biology. In particular, due to 
their unique role in post-transcriptional regulation, miRNAs 
are essential to embryonic stem cell (ESC) biology as well as 
CSC. By serving as buffers to balance between ESC and 
CSC pluripotency, proliferation, and differentiation, miRNAs 
play important roles in the maintenance of ESCs and CSCs  
Figure 1. Biogenesis of microRNAs and effect of natural agents on miRNA regulated 
drug resistance, metastasis and recurrence of cancer. (a) MiRNAs are transcribed by 
RNA polymerase II into long pri-miRNA, which can be recognized and cleaved in the nucleus 
by Drosha, resulting in a hairpin precursor form called pre-miRNA. Then, the pre-miRNA is 
exported from the nucleus to the cytoplasm by Exportin 5 and RanGTP  and is further 
processed by Dicer, to produce a duplex molecule containing single-stranded mature miRNA 
and a miRNA* fragment. The miRNA: miRNA* duplex is unwound by helicase and the 
miRNA* fragment is degraded, whereas the mature miRNA molecule binds to an Argonaute 
(Ago) protein and incorporates into the RNA-induced silencing complex (RISC). The 
RISC–miRNA complex can then target mRNAs bearing a perfectly complementary target site 
for degradation or can repress the translation of an mRNA that shows imperfect 
complementarity with the small RNA. (b) Dependent on various factors, miRNA can have 
either an oncogenic role if the target mRNA is a tumor suppressor gene, or a tumor 
suppressive role if the target molecule is an oncogene. Natural agents can impact expression 
level of miRNAs and participate in gene expression regulation as well as impacting miRNA 
regulated drug resistance, metastasis and recurrence of cancer. Primary miRNA, pri-miRNA; 
precursor miRNA, pre-miRNA; Drosha, RNase III endonuclease; DGCR8, Di George 
syndrome critical region 8; Dicer, RNase III endonuclease; RISC, RNA-induced silencing 
complex; EMT, epithelial-to-mesenchymal transition. 
 
RNA & DISEASE 2016; 3: e861. doi: 10.14800/rd.861; © 2016 by Jacob Masika, et al. 
http://www.smartscitech.com/index.php/rd 
 
Page 4 of 17 
 
Table 1. miRNAs with Tumor Suppressor or Oncogenic Activities [22, 24, 58] 
miRNA Targeted molecules 
Tumor suppressor miRNAs 
let-7 RAS, PRDM1, HMGA2, c-Myc, E2F, cyclin D2, Bcl-XL 
miR-30b Bcl-2, KRAS, PI3KCD,  
miR-15/miR-16 Bcl-2, Wt-1, CCND1 
miR-34 E2F3, Notch1, CDK4, CDK5, c-Met, BCL-2,  SIRT1, HMGA2, p53, E2F3, Bcl-2 
miR-17-5p AIB1, E2F1, p21, BIM 
miR-29 MCL-1, TCL-1, DNMT3s, CCND2, Akt2 
miR-124 CDK6, STAT3, CCND2 
miR-127 Bcl-6 
miR-143 Ras, ERK5 
miR-145 Mucin1, ERG 
miR-181 Colorectal cancer 
miR-205 E2F1, LAMC1 
miR-375 PDK1, 14-3-3f, AEG-1, IGF1-receptor 
miR-31 Integrin alpha5, RhoA, MMP16, Radixin, WAVE3 
miR-203 Caveolin 1, LASP1 
miR-100 Mcl-2, mTOR, IGF1R, FKBP51 
miR-125a-3p P53 
miR-192 Caspase 7, VEGF-A, Bcl-2, Zeb2, PARP 
miR-449 p21, p53, Bcl-2,  
miR-200c FAP-1 
Oncogenic miRNAs 
miR-21 PTEN, TPM1, PDCD4, maspin, Bax, Bcl-2, Akt,  
miR-155 AT1R, TP53INP1, FoxO3a 
miR-17-92 Tsp1, CTGF, E2F1, AIB1, TGFBR2, PTEN, RB2, NF-ΚB, Bim 
miR-106a RBL1/2 
miR-373 LATS2 
miR-197 ACVR1, TSPAN3, FUS1 
miR-221 KIT, p27(Kip1), p57, PTEN, Cx43 
miR-222 KIT, p27(Kip1), p57, PTEN, Cx43 
miR-372 LATS2 
miR-301 FoxO2, BBC3, PTEN, COL2A1 
miR-31 Akt, ABCB9, RhoA, radixin, integrin-25 
miR-92a FoxO1, Bim 
miR-196a HOXA5, ING5 
miR-181a/b AC9, PRKCD 
miR-141 YAP1 
 
and their transition between self-renewal, proliferation and 
differentiation. Naturally, miRNAs are often associated with 
novel therapeutic ideas. Several examples exist, wherein they 
have already been successfully implemented to break barriers 
in treatment of various diseases [35]. However, studies have 
also revealed that dysregulated miRNAs target oncogenes, 
tumor suppressor genes, and transcription factors (Table 1) 
and inhibition and/or overexpression of these miRNAs affect 
cell migration, invasion, proliferation, and apoptosis (Figure 
3). If the recent research reports on microRNAs is anything 
to go by, then there is much potential for their clinical 
applications in the context of regenerative medicine and 
cancer treatment.  
Interestingly, natural agents have been reported to 
modulate the expression of individual miRNAs by a 
relatively small increment [36, 37]. However, these natural 
agents have the ability to simultaneously regulate multiple 
putative tumor suppressor and oncogenic miRNAs (Table 2). 
Although it is yet to be determined whether the combined 
modulation of miRNAs or targeting one key miRNA has a 
superior therapeutic effect, emerging scientific evidence 
suggests that coordinated regulation of multiple miRNAs 
may result in synergistic tumor growth suppression [38]. 
Theoretically, co-regulation of multiple miRNAs could 
minimize unwanted upregulation of oncogenes, while 
maintaining upregulation of tumor suppressor genes. Thus, 
use of agents that targets multiple miRNAs could be more 
effective and safer strategy for cancer treatment and 
prevention than targeting individual miRNAs. 
Cancer stem cells (CSCs) 
Enough scientific evidence exists to suggest that the 
majority of cells in solid tumors are of non-tumorigenic 
origin. Cancer stem cells (CSCs) have been reported in many 
human tumors and are proposed to drive tumor initiation, 
progression maintenance, invasiveness, metastasis, drug 
resistance, and recurrence. CSCs share a variety of biological 
properties with normal somatic stem cells such as 
self-renewal, asymmetric cell division, differentiation, 
chemoresistance and the expression of specific stem cell 
genes [39, 40]. The CSC theory, which is based on the concept 
that cancer might arise from a rare population of cells with 
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stem cell properties, is generally accepted in the field of 
cancer biology and research, and in particular with regard to 
cancer drug discovery. Despite their potential clinical 
importance, the regulation of CSCs at the molecular level is 
not well-understood. Normal stem cells and CSCs act via 
various common signaling pathways that regulate 
self-renewal activity, including Wnt, Notch, and Sonic 
Hedgehog, and dysregulation of these pathways is reported 
to play an important role in tumor initiation and development 
[41]. A study by Jamieson and colleagues demonstrated that 
aberrations in the Wnt/β-catenin pathway enhanced 
self-renewal activity during leukemia stem cell propagation 
[42]. On the other hand, a study by Korkaya and coworkers 
reported that the Wnt/β-catenin pathway was involved in the 
regulation of normal and malignant mammary 
stem/progenitor cell populations [43]. Accumulating lines of 
evidence have revealed that Notch pathway is activated in 
breast, glioblastoma, and colon CSCs [44, 45] while alterations 
in Hedgehog signaling have been reported in colon, breast, 
and glioblastoma CSCs [46, 47]. It is now widely accepted that 
altered stem cell self-renewal is essential for cancer 
initiation, growth, and relapse and that CSCs play a critical 
role in cancer cell biology. Therefore, identification of 
specific CSCs markers may be important in the discovery 
and development of novel oncology treatment options. So 
far, the role of CSCs in cancer metastasis and drug resistance 
is undisputable [48-50]. CSCs are endowed with very tight 
regulatory framework to ensure their sustenance and 
overwhelming evidence support the role of epigenetics in 
regulation of CSCs [51]. Irrespective of the resident CSC 
theory, it is beyond doubt that the agents capable of targeting 
CSCs stand a better chance as cancer therapeutic options 
What’s more, CSCs are resistant to conventional treatments 
and are therefore not only of academic interest, but may also 
be an important consideration in clinical practice. Therefore, 
a better understanding of the characteristics of CSCs and the 
identification of therapeutic agents capable of targeting the 
CSC population are critical issues.  
Modulation of miRNAs by natural agents 
A number of reports, including some from our laboratory, 
have documented the modulation of miRNAs by natural 
agents [52-56]. Since epigenetic alterations play important roles 
in aberrant expression of several miRNAs in cancer cells, 
natural agents are now being investigated for their ability to 
reverse these changes that will ultimately lead to inhibition 
of tumor growth, invasiveness and metastasis. 
To date, many of the anticancer agents currently used in 
cancer therapies have been developed from natural products 
such as plants (vincristine, vinblastine, etoposide, paclitaxel, 
camptothecin, topotecan, and irinotecan), marine organisms 
(cytarabine), and microorganisms (dactinomycin, bleomycin, 
and doxorubicin) [57]. MiRNAs are being considered as 
attractive targets for cancer prevention and therapy due to 
their oncogenic or tumor suppressor activities [58] (Table 1). 
Various studies have suggested that the modulation of 
miRNAs serves as one of the key mechanisms in the 
anticancer activities of a variety of natural agents (Table 2). 
Additionally, mechanistic studies have demonstrated that 
they exert their antiproliferative and/or proapoptotic effects 
to prevent the occurrence and/or spread of various cancers by 
targeting numerous key elements in intracellular signaling 
Figure 2. Altered miRNA expression affects signaling pathways to enhance carcinogenesis. 
Representative miRNA are depicted that have been shown to act as oncogenes or tumor suppressor 
genes to affect the most common hallmarks of cancer. miRNA, microRNA. 
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network involved in carcinogenesis [59]. Here we describe 
some of the natural agents which are known to regulate 
miRNA expression in cancer. 
Curcumin 
Curcumin, the principle curcuminoid and a derivative of 
the spice turmeric curcuma longa, is used as a naturally 
occurring medicine to treat variety of inflammatory disorders 
and human cancers [60]. A study by Sun and colleagues 
reported upregulation of 11 miRNAs and downregulation of 
18 miRNAs in curcumin-treated pancreatic cancer cells [61]. 
They reported that miR-22 was upregulated upon curcumin 
treatment, and the predicted targets were ERα and 
transcription factor Sp1, while miR-196, an oncogenic 
miRNA in gastric cancers, was significantly downregulated 
after curcumin treatment [61]. Curcumin has been shown to 
downregulate putative oncogenic miRNAs, such as miR-21 
[62, 63], while it upregulates key tumor-suppressor miRNAs, 
including miR-200 family, let-7 family, miR-185b, and 
miR-22 [64, 65, 66]. More recently, Toden and colleagues 
reported that curcumin chemosensitizes colorectal cancer 
cells to 5-fluorouracil (5FU) by suppression of 
epithelial–mesenchymal transition (EMT) through 
upregulation of EMT-suppressive miRNAs in 5-fluorouracil 
resistant (5FUR) cell lines. Furthermore, they reported that 
the curcumin-mediated chemosensitization of 5FU-resistant 
cells can be further controlled through modulation of 
miR-200c expression [37]. In another study they demonstrated 
that curcumin and AKBA induced upregulation of miR-34a 
and downregulation of miR-27a in colorectal cancer cells [36]. 
A study by Yang et al. has shown that curcumin 
upregulated miR-15a and miR-16 in MCF-7 breast cancer 
cells which caused an induction of apoptosis [67]. Curcumin 
has also been shown to induce tumor suppressor miR-186 
expression to promote apoptosis in lung cancer [68]. Zhao et 
al. reported that curcumin exerts its cytotoxic effects against 
SKOV3 ovarian cancer cells largely through upregulation of 
miR-9 [69]. Another tumor suppressor, miR181b, has been 
demonstrated to be induced by curcumin, and it inhibits 
breast cancer metastasis [65]. High levels of miR-221 
expression have been correlated with shorter survival in 
pancreatic cancer patients, suggesting that miR-221 could be  
Figure 3. Natural agents alter the expression of miRNAs. Regulation of miRNAs 
by natural agents and effects of miRNA inhibition or overexpression on (a) cell 
migration, invasion, proliferation, and (b) apoptosis. AKBA, 3 
acetyl-11-keto-β-boswellic acid; DIM, 3,3΄-diindolylmethane; EGCG, 
epigallocatechin-3-gallate; 13C, Indole-3-Carbinol; miR, microRNA. 
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Table 2. Natural agents regulation of miRNAs in cancer. Modulation of miRNA expression by certain natural agents and 
effect on cancer biology 
Natural agent miRNA Function Reference 
1. Resveratrol ↑miR-141, miR-663, miR-34a, miR-744, miR-622 and 
miR-200c 
↓miR-17, miR-21, miR-25, miR-92a-2, miR-103-1, 
and miR-103-2 
Invasiveness, EMT, and metastasis [88-94] 
 
2. EGCG ↑miR-16, miR-210, miR-7-1, miR-34a, and miR-99a 
↓miR-21, miR-98-5p, miR-92, miR-93, and miR-106b 




3. Genistein ↑miR-16, miR-574-3p, miR-1296 







4. Curcumin ↑miR-15a, miR-16, miR-34a, miR-186, miR-22, 
miR-200 family, let-7 family, miR-185b, miR-181a 
↓miR-21, miR-221, miR-27a, miR-199a, miR-98, 















7. DIM ↑miR-21, miR-200b, miR-200c, let-7b, let-7c, let-7d, 
let-7e, and miR-146a 
↓miR-200, miR-221, miR-92a 
Growth, EMT, drug resistance, 
invasion, and metastasis 
[70,85,86,111, 
112] 
8. I3C ↓miR-21, miR-31, miR-130a, miR-146b, and miR-377 Proliferation [110,113, 
 114] 






10. Baicalin ↑miR-378, miR-199a-3p, miR-181b 
↓miR-23a, miR-294 
DNA repair  
Apoptosis, Proliferation 
[56, 73,75] 





12. Sulforaphane ↑miR-200c, miR-140 EMT [119, 121] 
13. ACA ↓miR-23a Proliferation, apoptosis [117, 118] 





Abbreviations: I3C: Indole-3-Carbinol; ACA: 1΄S-1΄-acetoxychavicol acetate; AKBA: 3 acetyl-11-keto-β-boswellic acid; CPT: 
Camptothecin; DIM: 3,3΄-Diindolylmethane; EGCG: Epigallocatechin-3-Gallate; EMT: Epithelial-to-Mesenchymal Transition; 
miR: microRNA; Rh2: Ginsenoside Rh2. 
an oncogenic miRNA [70]. In another study, curcumin 
treatment resulted in the upregulation of tumor suppressor 
miR-203 in bladder cancer that led to apoptosis induction 
and diminished proliferation, migration, and invasion [71]. 
Importantly, in a study by Zhang and colleagues regarding 
curcumin and multi-drug resistance, reported that alterations 
were detected in 342 miRNAs [68]. Curcumin treatment led to 
significant changes (> 2.5 fold) in various oncogenic and 
tumor suppressor miRNAs. A key target was miR-186*, 
which promoted apoptosis in cancer cells. Taken together, 
these studies provide evidence for the idea that diet-induced 
miRNAs may play an important role in overcoming drug 
resistance in cancers. 
Boswellic acid 
Boswellic acid (3 acetyl-11-keto-β-boswellic acid-AKBA) 
upregulates the key putative tumor-suppressive miRNAs of 
the let-7 and miR-200 family in colorectal cancer and the 
expression of these miRNAs inversely corresponds with 
tumor size and volume in a xenograft animal model [72]. 
AKBA suppresses tumor growth by inducing upregulation of 
tumor-suppressive miR-34a and downregulation of miR-27a 
in colorectal cancer cells [36]. Curcumin and AKBA acts 
synergistically to exert antitumorigenic effects in colorectal 
cancer cells, in both in vitro and in vivo experimental 
models. Combined bioinformatics and in silico analysis 
identifies apoptosis, proliferation, and cell-cycle regulatory 
signaling pathways as key modulators of AKBA-induced 
anticancer effects. Therefore, regulation of miRNAs appears 
to be a crucial antitumorigenic mechanism of AKBA and 
warrants further systematic and comprehensive investigation. 
Baicalin 
Baicalin alters the expression pattern of miRNAs in 
ultraviolet radiation B (UVB) treated mice compared to 
controls [73]. Three miRNAs (miR-378, miR-199a-3p and 
miR-181b) are downregulated while one miR-23a is 
upregulated in baicalin treated mice compared with UVB 
irradiated mice. These miRNAs are predicted to be related to 
DNA repair signaling pathway. Our recently published data 
revealed that baicalin inhibited ESCs proliferation with 
increase of cells in G1-phase and a decrease in S phase [56] 
(Figure 4). Baicalin downregulates proto-oncogenes c-jun 
and c-fos as well as down-regulation of miR-294 expression 
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in mESCs while overexpression of miR-294 in mESCs 
reverses the alterations in the mESC proliferation and the 
expression of c-jun and c-fos induced by baicalin. Our results 
are in good agreement with the observations in cancer cells 
and vascular smooth muscle cells (VSMCs) [74, 75]. Since 
recent reports have implicated miRNAs in the regulation of 
proliferation, differentiation and apoptosis in cancer cells and 
ESCs, it seems possible that miRNAs might also contribute 
to the cellular mechanisms of decreased proliferation and 
differentiation and increased apoptosis induced by baicalin in 
cancer cells. Studies on miRNA modulation by baicalin in 
cancer cells are limited and therefore more investigations are 
needed to determine the miRNA regulatory effect of baicalin 
in ESCs and cancer cells with a view of translating such 
findings into clinical therapeutic applications. 
Genistein 
Genistein is an important polyphenol that has shown 
significant anticancer effects through the regulation of 
miRNAs. Genistein treatment enhances apoptosis 
synergistically with miR-16 in human chronic lymphocytic 
leukemia cells [76]. In prostate cancer, genistein both 
downregulates miR-221 and miR-222 and restores tumor 
suppressor gene aplasia Ras homolog member I (ARHI) 
expression, which ultimately results in anticancer effects [77]. 
In prostate cancer, genistein inhibits the migration and 
invasion of PC3 and DU145 cells through downregulating 
oncogenic miR-151 [78]. Treatment of ovarian and pancreatic 
cancer cells with genistein causes inhibition of cell growth 
and migration through suppression of miR-27a [79, 80]. 
Furthermore, genistein upregulates the tumor suppressor 
miR-574-3p in prostate cancer cells [81], and exerts its 
antitumor effect in prostate cancer via downregulation of 
miR-1260b [82]. Genistein treatment downregulates 
oncogenic miR-1260b and results in inhibition of 
Wnt-signaling in renal cancer cells [82].  
Additionally, miR-223 expression is downregulated in 
pancreatic cancer cells after genistein treatment that 
correlated with cell growth inhibition and induction of 
apoptosis [83]. Genistein also upregulates miR-146a in 
pancreatic cancer cells, inhibiting their invasive potential by 
downregulating EGFR, NFκB, IRAK-1, and MTA-2 [84]. In 
another study, Li et al. reported a differential effect in 
gemcitabine-resistant versus gemcitabine-sensitive pancreatic 
cancer cells. They reported that miRNAs of miR-200 and 
let-7 families were downregulated in gemcitabine-resistant 
cells versus gemcitabine-sensitive cells, however, isoflavone 
treatment increased both miR-200 and let-7 family miRNAs 
by modulating EMT transcription factors, such as vimentin, 
slug, and ZEB1 [85]. In another study, prostate cancer cells 
Figure 4. Effects of Baicalin on mESCs proliferation, expression of proto-oncogenes 
and expression of members of miR-290 cluster. (a) Baicalin 50 μM inhibited the 
proliferation of mESCs to 0.55 ± 0.04 vs. control (p<0.01, n=14). (b) Baicalin administration 
led to accumulation mESCs in G1and G2/M phases compared to controls (p<0.05, n=4). (c) 
Baicalin 50 μM administration resulted in down-regulation of proto-oncogenes c-jun and c-fos 
(p<0.05, n=5). (d) Baicalin 50 μM treatment led to down-regulation of miR-294 (p<0.05, n=4) 
with no significant effect on the other members of miR-290 cluster (p>0.05, n=4). 
(Reproduced and modified from [56]). 
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treated with genistein and the researchers reported that 
minichromosome maintenance 2 gene (MCM2) was 
downregulated by miR-1296 and genistein induced the 
expression of miR-1296 by up to five-fold, along with cell 
cycle arrest in S-phase [86]. Furthermore, genistein was also 
investigated in other cancer models, such as human uveal 
melanoma cells [87]; using both in vitro and in vivo models, 
miR-27a was found to be downregulated with concomitant 
upregulation of its target gene, ZBTB10. 
Resveratrol 
Resveratrol (3,4΄,5-trihydroxystilbene) is a natural 
phytoalexin in several plants, such as grapes, berries, plums, 
and peanuts. It has anticancer activities against various 
cancers including breast cancer, lung cancer, glioma, prostate 
cancer, colon cancer, and neuroblastoma [88, 89]. It reduces the 
expression of numerous oncogenic miRNAs, namely, 
miR-17, miR-21, miR-25, miR-92a-2, miR-103-1, and 
miR-103-2, in human colon cancer cells [90]. In the same 
study, tumor suppressor miR-663 levels are restored in 
human colon cancer cells after treatment of resveratrol. In 
another study, resveratrol treatment upregulates miR-141 and 
results in a significant reduction of invasiveness, whereas 
resveratrol-induced miR-200c expression causes reversal of 
EMT through downregulation of Zeb1 and upregulation of 
E-cadherin [91]. The anticancer effect of resveratrol in 
pancreatic cancer cells is proposed to due to inhibition of 
oncogenic miR-21 [92]. Moreover, the synergistic antitumor 
activity of resveratrol and miR-200c has been demonstrated 
in human lung cancer cells [93]. In colon cancer cells, 
resveratrol inhibits the cell growth and induces apoptosis 
through up-regulating miR-34a expression [94]. 
Epigallocatechin-3-gallate (EGCG) 
Epigallocatechin-3-gallate (EGCG) is a polyphenol 
flavonoid of natural green tea that possesses significant 
antioxidant and anticancer properties [95]. EGCG increases 
the expressions of 13 miRNAs including miR-16 and 
decreases the levels of 48 miRNAs in HepG2 human hepatic 
cancer cells [96]. EGCG induces apoptosis in hepatocellular 
carcinoma through enhanced expression of miR-16 [96]. 
Increased expression of miR-16 results in inhibition of its 
target antiapoptotic Bcl-2, followed by mitochondrial 
dysfunction, cytochrome c release, and subsequent apoptosis. 
EGCG also inhibits the expression of miR-21 followed by 
repression of androgen receptor (AR) signaling and, 
consequently, a reduction of prostate cancer cell growth [97]. 
In lung cancer, EGCG upregulates the expression of 
miR-210, which leads to the inhibition of proliferation and 
anchorage-independent growth [98]. EGCG enhances the 
efficacy of cisplatin through downregulation of miR-98-5p in 
A549 non-small lung cancer cells [99]. A combination of 
N-(4-hydroxyphenyl) retinamide and EGCG decreases the 
expression of oncogenic miRs (miR-92, miR-93, and 
miR-106b) and enhances the expression of tumor suppressor 
miRs (miR-7-1, miR-34a, and miR-99a) which results in 
growth inhibitory effects in human malignant neuroblastoma 
cells [100]. All of these experiments have indicated that EGCG 
has the potential to inhibit cancer growth via miRNAs 
although much more studies are warranted. 
Quercetin 
Quercetin, a flavonoid found in onions, apples, tea, and 
red wine, upregulates miR-142-3p in pancreatic ductal 
adenocarcinoma cells [101]. Indeed, intake of a quercetin-rich 
diet modulates the expression of 48 unique miRNAs [102]. 
These miRNAs have been reported to decrease tumor 
metastasis and invasion (miR-146a/b, 503, and 194), inhibit 
cell proliferation (miR-125a, 155, let-7 family, 302c, 195, 
26a, 503, and 215), induce apoptosis (miR-125a, 605, 26b, 
let-7g, 34a, 491, and 16), and upregulate tumor suppressor 
miRNAs (let-7 family, miR-125a, 183, 146a, 98, 19b, 106a, 
and 381) [102]. Recently, Del Follo-Martinez et al. reported 
that quercetin treatment induced apoptosis in colorectal 
cancer cells when used along with resveratrol [103]. The 
underlying mechanism of apoptosis induction was closely 
related to the downregulation of oncogenic miR-27a [103]. In 
another study, quercetin, when used with catechins, enhanced 
the expression of let-7 in pancreatic cancer cells followed by 
K-ras inhibition and reduction of the advancement of 
pancreatic cancer [55]. Furthermore, the upregulation of 
miR-146a, a negative regulator of NF-𝜅B activation, by 
quercetin protects CCD-180Co colonic myofibroblast cells 
against ROS [104]. 
Camptothecin (CPT) 
Camptothecin, an alkaloid isolated from bark of 
Camptotheca acuminata, is a potent chemotherapeutic agent 
against a variety of tumors [105-108]. CPT reduces the 
expression of miR-125b significantly, which led to the 
upregulation of Bak1 and p53 and resulted in apoptosis of 
human cervical cancer and myelogenous leukemia cells [107]. 
In a recent study, camptothecin inhibits HIF-1α by enhancing 
the levels of miR-155, miR-17-5p, and miR-18a in HeLa 
cells [109]. 
Indole-3-Carbinol (I3C) and Diindolylmethane (DIM) 
Diindolylmethane is an active compound that is generated 
in the stomach through the metabolic conversion of 
Indole-3-carbinol (I3C), present in cruciferous vegetables 
such as cabbage, broccoli, cauliflower, kale, radish, turnip, 
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and brussels sprouts [110]. DIM regulates the expression of 
numerous miRNAs involved in cancer development and 
progression. It induces the expression of certain miRNAs, 
such as miR-200 and let-7 families, that leads to the reversal 
of EMT and enhanced chemosensitivity in 
gemcitabine-resistant pancreatic cancer cells [84, 85]. DIM also 
induces the expression of miR-146a, which reduces 
pancreatic cancer cell invasion via inhibition of 
metastasis-associated protein 2 (MTA-2), interleukin-1 
receptor-associated kinase 1 (IRAK-1), and NFκB [84]. Jin 
observed that DIM inhibited breast cancer cell growth by 
enhancing the expression of miR-21 which led to the 
degradation of its target Cdc25A [111]. Formulated 
3,3-diindolylmethane (BR-DIM) is capable of 
downregulating miR-221, resulting in growth inhibition of 
pancreatic cancer cells and patients with high expression of 
miR-221 are reported to have a relatively shorter survival 
compared to those with lower expression[70]. DIM can 
downregulate miR-92a which is associated with receptor 
activator of nuclear factor-𝜅B ligand (RANKL) signalling, 
EMT, and cancer progression to inhibit differentiation of 
osteoclasts and osteoblasts in prostate cancer metastasis [112]. 
Remarkably, upregulation of miR-21, miR-31, miR-130a, 
miR-146b, and miR-377 observed in vinyl 
carbamate-induced lung cancer in mice is reversed by I3C 
[113]. PTEN, PDCD4, and reversion-inducing-cysteine-rich 
protein with Kazal motifs (RECK) are identified as potential 
targets of miR-21 [113]. Recently, a study by Paik and 
colleagues reported that 13C downregulated miR-21 in 
Panc-1 pancreatic carcinoma cells. Overexpression of 
miR-21 negated I3C-induced sensitivity towards gemcitabine 
and reduced the expression of its target, PDCD4, which was 
upregulated by I3C [114]. Taken together, these encouraging 
results show that DIM and I3C could be harnessed as 
potential anticancer therapeutic agents.  
Ginsenoside Rh2 
Ginsenoside Rh2 is a biologically active phytochemical 
extracted from Ginseng, a commonly used alternative drug 
taken orally in traditional herbal medicines in China, Korea, 
Japan and some Western countries [115]. It is a triterpene 
saponin, consisting of a steroid nucleus and a sugar moiety 
[115]. Ginsenoside Rh2 altered miRNA expression in human 
glioma U251 cells, including up-regulating 14 and 
down-regulating 12 miRNAs.  Ginsenoside Rh2 also exerts 
its anti-proliferative effect in human glioma cells in part by 
up-regulation of miRNA-128 expression [116], while 
down-regulating miR-21 which leads to glioma cell 
apoptosis and cell growth inhibition, reduced invasiveness 
and suppressed tumorigenicity [116]. Further studies are 
needed to investigate the molecular mechanism of 
Rh2-induced down-regulation of miR-21 as an 
anti-proliferative effect in cancer cells and to firmly establish 
these study findings so as to expedite translation of such 
findings into efficacious clinical applications. 
1΄S-1΄-acetoxychavicol acetate (ACA) 
Recently, Phuah and colleagues [117] reported that a total of 
25 miRNAs were found to be significantly differentially 
expressed following treatment with 1΄S-1΄-acetoxychavicol 
acetate (ACA), a natural compound isolated from the wild 
ginger, Alpinia conchigera, and/or cisplatin on Ca Ski and 
HeLa cervical carcinoma cells. These included miR-138, 
miR-210, and miR-744 with their predicted targets involved 
in signaling pathways regulating apoptosis and cell cycle 
progression [117]. Another study reported that ACA 
downregulated miR-23a in HN4 head and neck Squamous 
cells and its inhibition suppressed cell proliferation and 
induced apoptosis, with PTEN confirmed as its target [118]. 
Sulforaphane 
Sulforaphane, an isothiocyanate, is derived from 
cruciferous vegetables such as broccoli and broccoli sprouts. 
It upregulates 15 miRNAs (miR-372, miR-342-3p, 
miR-486-5p, miR-9, miR-9, miR-145, miR-146a, miR-629, 
miR-505, miR-758, miR-30a, miR-27b, miR-135b, miR-27b, 
and miR-23b) while downregulating 3 miRNAs (miR-633, 
miR-155, and miR-106a) in NCM460 and NCM356 normal 
colon epithelial cells [119]. In sulforaphane-treated T24 
bladder cancer cells, miR-200c is upregulated, leading to 
inhibition of EMT and metastasis. Downregulation and 
overexpression of miR-200c reverses and enhanced ZEB1 
repression and E-cadherin induction by sulforaphane, 
respectively [120]. MiR-140 is upregulated following 
sulforaphane treatment in MCF10DCIS and MDA-MB-231 
breast cancer cells. Both SOX9 and aldehyde dehydrogenase 
1 (ALDH1) are also identified as targets of miR-140 and 
miR-140 overexpression downregulated the protein levels in 
both targets [121]. Recently, sulforaphane was reported to 
complement with quercetin and catechins in elimination of 
advanced pancreatic cancer by miR-let-7 induction and K-ras 
inhibition [55]. Further research is warranted to firmly 
establish these research findings and explore the possibility 
of the use of sulforaphane as a cancer therapeutic adjuvant 
option.  
Ellagitannins 
Ellagitannins are polymeric polyphenols abundant in 
strawberries, raspberries, almonds, walnuts, and various 
other fruits and nuts. These are polyesters of ellagic acid and 
a sugar moiety and upon hydrolysis release ellagic acid. 
Ellagitannins have been reported to exhibit anti-oxidant, 
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radical scavenging, antiviral, antimicrobial, anti-mutagenic, 
anti-inflammatory, anti-tumor promoting and 
immunomodulatory properties [122]. Ellagitannins modulate 
transcription factors and signaling pathways which inhibit 
cancer cells proliferation and induce their apoptosis. For 
example, liver cancer cells exposed to ellagitannin BJA3121, 
isolated from a plant Balanophora japonica exhibited cell 
growth inhibition and alteration in the expression of several 
miRNAs. Using a dose- and time-dependent strategy, 17 
miRNAs were found to be upregulated and 8 miRNAs were 
downregulated following treatment of HepG2 cells. These 
included upregulation of miR-let-7e, miR-370, miR-373 and 
miR-526b and downregulation of let-7a, let-7c, let-7d which 
correlates with genes involved in cell differentiation and 
proliferation [123]. Prediction software and functional analyses 
identified likely targets with roles in cell proliferation and 
differentiation. However, the precise mechanisms await 
further studies. 
Role of nutritive natural agents in the regulation of 
miRNAs 
Studies have shown that dietary components such as 
folate, Vitamin D and retinoids could modulate miRNA 
expression then exert inhibitory effects on cancer [124]. 
Indeed, folic acid has been reported to down-regulate 
miR-10a [125], suggesting the regulatory role of dietary 
factors on miRNA. Hepatocellular carcinoma in rats fed a 
folate-deficient diet for 54 weeks was associated with 
upregulation of several miRNAs, including miR-21, and 
downregulation of liver-specific miR-122. Folate treatment 
increased suppressor miR-122 levels, and was associated 
with inhibition of tumorigenesis, suggesting a potential 
chemoprevention paradigm affecting miRNAs [126].  On the 
contrary, vitamin E deficiency in rats decreased tumor 
suppressor miRNAs in the liver. Vitamin E has also has been 
reported to modulate lipid metabolism, inflammation, and 
other cancer-associated pathways by reducing the expression 
of miR-122 and miR-125b [127]. 
Vitamin D has long been considered as an essential 
nutrient for human health and evidence from epidemiologic 
and experimental studies have indicated that higher intakes 
of vitamin D from food and/or supplements leads to higher 
blood levels of vitamin D, which are highly associated with 
reduced risks of certain cancers [128, 129]. Vitamin D and its 
metabolites, 1,25-dihydroxyvitamin D3 (1, 25D3) and 
25-hydroxyvitamin D3 (25(OH)D3), regulate miRNA profiles 
in different cancers. In one study, human myeloid leukemia 
cells treated with 1,25D3 displayed downregulation of 
miR-181a and miR-181b and enhanced expression of 
p27Kip1 and p21Cip1, as well as G1 cell cycle arrest [128]. It 
has been reported that 25(OH)D3 could modulate p53 and 
PCNA levels, alter miR-182 expression, and contribute to a 
protective role against cellular stress in breast epithelial cells 
[129]. Importantly, cancer chemopreventive effects of vitamin 
D and its metabolites are thought to be mediated via binding 
with its receptor (VDR). MiR-125b is identified as having a 
potential sequence match in the 3’-UTR region of human 
VDR mRNA, suggesting a pathway for targeted therapy via 
VDR downregulation in human cancers [130]. Nonetheless, 
the precise role of vitamin D on the CSC-related miRNAs is 
not yet clear. Therefore, further investigations are required to 
elucidate the role of vitamin D in the regulation of CSC 
characteristics and miRNAs in the development and 
progression of cancer. 
Retinoic acid (RA) is an active metabolite of vitamin A, it 
is involved in cellular differentiation by modulating miRNA 
expression in various cells, including acute promyelocytic 
leukemia [131] and neuroblastoma cell lines [132]. In cells 
derived from acute promyelocytic leukemia patients after 
incubation with 100 nmol/L all-trans retiRA, eight miRNA 
were upregulated (miR-15a, miR-15b, miR-16–1, let-7a-3, 
let-7c, let-7d, miR-223, miR-342, and miR-107) and one was 
downregulated (miR-181b) [131]. It is proved that RA 
upregulates let-7a-3 by inducing NF-kB that binds to the 
promoter of the let-7a-3 gene. Furthermore, all-trans-RA 
downregulates K-Ras and Bcl2 and correlates with the 
activation of known miRNA regulators of those proteins, 
let-7a and miR-15a/miR-16–1, respectively [131]. Taken 
together, these results reveal that miRNAs could be useful as 
biomarkers for cancer prevention, treatment, diagnosis and 
prognosis and as such assessing nutritional status in dietary 
intervention studies could be of great value. 
A study by Davidson et al. evaluated the chemopreventive 
effects of n-3-Polyunsaturated fatty acids (n-3 PUFAs) on 
azoxymethane-induced colon cancer in rats [133]. Carcinogen 
significantly downregulated of five known tumor suppressor 
miRNAs, which were reversed upon exposure to n-3 
PUFA[133]. Based on transfection experiments in vitro, tumor 
suppressor protein, PTEN was found to be targeted by 
oncogenic miR-21 in human colon cancer cells. Additionally, 
beta site amyloid precursor protein-cleaving enzyme 
(BACE-1) was targeted by tumor suppressor miR-107 and 
was downregulated in carcinogen-induced tumor tissues 
compared with normal colonic mucosa [133]. The 
chemoprotective role of dietary n-3 PUFAs by modulating 
miRNA was evidenced in this study. Similarly, short chain 
fatty acids which inhibit HDAC activity, such as butyrate, 
are also reported to alter miRNA patterns regulating 
endodermal differentiation mechanisms, as studied in human 
embryonic stem cells [134]. 
Other natural agents 
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A study by Wang and colleagues reported that Ursolic 
acid, a pentacyclic triterpene acid found in medicinal herbs 
such as Oldenlandia diffusa and Radix actinidiae, induced 
apoptosis in U251 glioblastoma cells by downregulating 
miR-21 and inducing the expression of PDCD4, a target of 
miR-21. Overexpression of miR-21 suppressed the Ursolic 
acid-induced expression of PDCD4 [135]. Garcinol, a 
polyisoprenylated benzophenone derivative obtained from 
Garcinia indica extracts, reverses EMT in MDA-MB-231 
and BT-549 breast cancer cells as well as in xenograft mouse 
model through upregulation of let-7a, let-7e, let-7f, 
miR-200b, and miR-200c. Additionally, inhibition of 
miR-200a, miR-200b, and miR-200c attenuates the 
garcinol-mediated inhibition of invasion [54]. Matrine, an 
alkaloid isolated from Sophora flavescens, downregulates 
miR-21 to induce overexpression of PTEN and inactivate 
Akt, leading to cell cycle arrest and apoptosis in MCF-7 
breast cancer cells [136]. More recently, a study by Cufı΄ et al., 
reported that a water-soluble formulation of the flavolignan 
silibinin, the bioactive constituent of silymarin isolated from 
the dried fruits of the milk thistle, Silybum marianum plant 
[137], was able to reverse the epithelial-to-mesenchymal 
transition (EMT)-related high miR-21/low miR-200c 
microRNA signature and repressed the mesenchymal 
markers SNAIL, ZEB, and N-cadherin observed in 
erlotinib-refractory non-small cell lung cancer (NSCLC) 
tumors [138]. Isothiocyanates, such as phenethyl 
isothiocyanate (PEITC) has been proposed to be a useful 
chemopreventive agent that can inhibit carcinogenic process. 
In one study, PEITC strongly counter-regulated the 
expression of majority of miRNAs downregulated by 
cigarette smoke which included;  miR-125b, miR-26a, 
miR-146-pre, let-7a, let-7c, miR-192, miR-222-pre, miR-99 
and miR-123 designated for TGF-β expression, NF-κB 
activation, Ras activation, cell proliferation, apoptosis and 
angiogenesis [139]. On the other hand, Selenium deficiency 
increases cancer risk. A study by Sarveswaran and colleagues 
has demonstrated that selenium activated p53 and increased 
its targets in the miR-34 family [140]. They reported that 
specific members of miR-34 family, miR-34b and miR-34c, 
but not miR-34a, increased significantly in prostate cancer 
cells treated with sodium selenite (an inorganic form of 
selenium). However, it is necessary to test these effects on a 
case-by-case basis, including their metabolites because of the 
toxicity concerns associated with inorganic and some organic 
forms of selenium [141- 143]. 
Conclusion and Future Perspective 
Based on the studies mentioned in this review, it is clear 
that natural agents modulate miRNAs leading to cancer 
prevention. MiRNAs have been characterized as the 
biomarkers for diagnosis and prognosis, markers of risk 
stratification and targets for cancer therapeutics, thus 
becoming attractive targets for cancer therapy and other 
therapies. To that end, natural agents could target miRNAs, 
which in turn could enhance the efficacy of conventional 
cancer therapies. Thus, targeting miRNAs by natural agents 
could open newer avenues in the treatment of cancer and in 
the ESCs as research tools. Natural agents display an 
inimitable ability in modification of cancer biology by 
modulating the expression of miRNAs through a variety of 
mechanisms, namely, epigenetic, transcriptional, and miRNA 
processing. It is our perspectives that natural agents could 
alter miRNA expression profiles, therefore inhibiting cancer 
growth, inducing apoptosis, reversing EMT phenotype, and 
increasing drug sensitivity. Consequently, regulation of 
miRNAs by natural agents could be a novel strategy toward 
designing combination approaches with conventional 
therapies for the treatment and prevention of tumor 
recurrence and may ultimately lead to successful treatment 
outcome of patients diagnosed with cancers. Despite the 
promising and good results of anticancer activities by natural 
agents, there are some hurdles such as low bioavailability. To 
this end, different approaches will be required to overcome 
these caveats including chemical modification, synthetic 
formulations, delivery by nanoparticles, amongst others. 
Thus, it is hoped that these new strategies would prevent 
tumor recurrence and resistance towards conventional 
therapies, leading to improvement in the overall response and 
survival of cancer patients.  
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